ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antibody-oligonucleotide Conjugates (AOCs) Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-5H18379
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antibody oligonucleotide Conjugates AOCs Market Research Report 2024
BUY CHAPTERS

Global Antibody-oligonucleotide Conjugates (AOCs) Market Research Report 2025

Code: QYRE-Auto-5H18379
Report
June 2025
Pages:76
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio

Antibody-oligonucleotide Conjugates (AOCs) Market Size

The global market for Antibody-oligonucleotide Conjugates (AOCs) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ 525 million by 2031, growing at a CAGR of 147.2% during the forecast period.

Antibody-oligonucleotide Conjugates (AOCs) Market

Antibody-oligonucleotide Conjugates (AOCs) Market

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
This report aims to provide a comprehensive presentation of the global market for Antibody-oligonucleotide Conjugates (AOCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-oligonucleotide Conjugates (AOCs).
The Antibody-oligonucleotide Conjugates (AOCs) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-oligonucleotide Conjugates (AOCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-oligonucleotide Conjugates (AOCs) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antibody-oligonucleotide Conjugates (AOCs) Market Report

Report Metric Details
Report Name Antibody-oligonucleotide Conjugates (AOCs) Market
Forecasted market size in 2031 US$ 525 million
CAGR 147.2%
Forecasted years 2025 - 2031
Segment by Type
  • Site-specific Coupling
  • Random Coupling
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Denali Therapeutics, Gennao Bio, ChainGen Bio
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

What is the Antibody-oligonucleotide Conjugates (AOCs) Market size in 2031?

Ans: The Antibody-oligonucleotide Conjugates (AOCs) Market size in 2031 will be US$ 525 million.

Who are the main players in the Antibody-oligonucleotide Conjugates (AOCs) Market report?

Ans: The main players in the Antibody-oligonucleotide Conjugates (AOCs) Market are Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Denali Therapeutics, Gennao Bio, ChainGen Bio

What are the Application segmentation covered in the Antibody-oligonucleotide Conjugates (AOCs) Market report?

Ans: The Applications covered in the Antibody-oligonucleotide Conjugates (AOCs) Market report are Rare and Genetic Diseases, Cancer Treatment, Central Nervous System Disorders

What are the Type segmentation covered in the Antibody-oligonucleotide Conjugates (AOCs) Market report?

Ans: The Types covered in the Antibody-oligonucleotide Conjugates (AOCs) Market report are Site-specific Coupling, Random Coupling

Recommended Reports

Antibody Drug Conjugates

Oligonucleotide Therapeutics

RNA and Antisense Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Site-specific Coupling
1.2.3 Random Coupling
1.3 Market by Application
1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Rare and Genetic Diseases
1.3.3 Cancer Treatment
1.3.4 Central Nervous System Disorders
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue
3.1.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue (2020-2025)
3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-oligonucleotide Conjugates (AOCs) Revenue
3.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio
3.4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
3.5 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
3.6 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
3.7 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type
4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)
5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
8.2 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
9.2 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
9.4 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
10.2 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Avidity Biosciences
11.1.1 Avidity Biosciences Company Details
11.1.2 Avidity Biosciences Business Overview
11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.1.5 Avidity Biosciences Recent Development
11.2 Dyne Therapeutics
11.2.1 Dyne Therapeutics Company Details
11.2.2 Dyne Therapeutics Business Overview
11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.2.5 Dyne Therapeutics Recent Development
11.3 Tallac Therapeutics
11.3.1 Tallac Therapeutics Company Details
11.3.2 Tallac Therapeutics Business Overview
11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.3.5 Tallac Therapeutics Recent Development
11.4 Denali Therapeutics
11.4.1 Denali Therapeutics Company Details
11.4.2 Denali Therapeutics Business Overview
11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.4.5 Denali Therapeutics Recent Development
11.5 Gennao Bio
11.5.1 Gennao Bio Company Details
11.5.2 Gennao Bio Business Overview
11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.5.5 Gennao Bio Recent Development
11.6 ChainGen Bio
11.6.1 ChainGen Bio Company Details
11.6.2 ChainGen Bio Business Overview
11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.6.5 ChainGen Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Denali Therapeutics
Gennao Bio
ChainGen Bio
List of Tables
 Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Site-specific Coupling
 Table 3. Key Players of Random Coupling
 Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2025)
 Table 8. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2031)
 Table 10. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
 Table 11. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
 Table 12. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
 Table 13. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
 Table 14. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2020-2025)
 Table 16. Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-oligonucleotide Conjugates (AOCs) as of 2024)
 Table 17. Ranking of Global Top Antibody-oligonucleotide Conjugates (AOCs) Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antibody-oligonucleotide Conjugates (AOCs) Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Headquarters and Area Served
 Table 20. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
 Table 21. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2020-2025)
 Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2026-2031)
 Table 27. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2020-2025)
 Table 29. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2026-2031)
 Table 31. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Avidity Biosciences Company Details
 Table 47. Avidity Biosciences Business Overview
 Table 48. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 49. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 50. Avidity Biosciences Recent Development
 Table 51. Dyne Therapeutics Company Details
 Table 52. Dyne Therapeutics Business Overview
 Table 53. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 54. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 55. Dyne Therapeutics Recent Development
 Table 56. Tallac Therapeutics Company Details
 Table 57. Tallac Therapeutics Business Overview
 Table 58. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 59. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 60. Tallac Therapeutics Recent Development
 Table 61. Denali Therapeutics Company Details
 Table 62. Denali Therapeutics Business Overview
 Table 63. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 64. Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 65. Denali Therapeutics Recent Development
 Table 66. Gennao Bio Company Details
 Table 67. Gennao Bio Business Overview
 Table 68. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 69. Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 70. Gennao Bio Recent Development
 Table 71. ChainGen Bio Company Details
 Table 72. ChainGen Bio Business Overview
 Table 73. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product
 Table 74. ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
 Table 75. ChainGen Bio Recent Development
 Table 76. Research Programs/Design for This Report
 Table 77. Key Data Information from Secondary Sources
 Table 78. Key Data Information from Primary Sources
 Table 79. Authors List of This Report


List of Figures
 Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
 Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type: 2024 VS 2031
 Figure 4. Site-specific Coupling Features
 Figure 5. Random Coupling Features
 Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2024 VS 2031
 Figure 8. Rare and Genetic Diseases Case Studies
 Figure 9. Cancer Treatment Case Studies
 Figure 10. Central Nervous System Disorders Case Studies
 Figure 11. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered
 Figure 12. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region: 2024 VS 2031
 Figure 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players in 2024
 Figure 16. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 17. The Top 10 and 5 Players Market Share by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
 Figure 18. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
 Figure 20. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
 Figure 24. Germany Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Ireland Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2031)
 Figure 32. China Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia & New Zealand Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
 Figure 40. Mexico Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
 Figure 44. Israel Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Avidity Biosciences Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 48. Dyne Therapeutics Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 49. Tallac Therapeutics Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 50. Denali Therapeutics Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 51. Gennao Bio Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 52. ChainGen Bio Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
 Figure 53. Bottom-up and Top-down Approaches for This Report
 Figure 54. Data Triangulation
 Figure 55. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Antibody Oligonucleotide Conjugates AOC Drug Market Research Report 2024
Global Oligonucleotide Bioconjugation Service Market Research Report 2024
Global GalNAc Oligonucleotide Conjugates Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
Global Antisense Oligonucleotides Market Research Report 2024
Global Antibody Oligonucleotide Conjugates AOC Drug CDMO Market Research Report 2024
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global Antisense ODN Market Research Report 2024
Global ASO based Drug Market Research Report 2024
Global Oligonucleotide Therapeutics Market Research Report 2024
Global Antibody drug Conjugates Market Insights Forecast to 2030
Global Antibody drug Conjugates for Tumors Market Research Report 2024
Global Oligonucleotide Drugs ONs Market Research Report 2025
Antibody drug Conjugate for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Conjugates Market Research Report 2024
Global Antibody drug Conjugates ADCs CMO and CDMO Market Research Report 2025
Global Antisense Oligonucleotide Service Market Research Report 2025
Global Antibody PMO Conjugates Market Research Report 2024
Global Nucleic Acid Aptamers Market Research Report 2025

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions